Advancing American Kidney Health

Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level

Retrieved on: 
Friday, October 6, 2023
Diagnosis, Partnership, Eli Lilly and Company, AKF, Senior, American Kidney Fund, Organization, Risk, Ingelheim am Rhein, Patient, Kidney, All, Advancing American Kidney Health, Kidney disease, Boehringer Ingelheim, Research, Pharmaceutical industry, Lilly

ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.

Key Points: 
  • ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.
  • Boehringer Ingelheim and Lilly’s membership helps fund AKF’s work to advance kidney disease awareness, prevention, early detection, treatment and research.
  • “AKF is pleased to continue our partnership with Boehringer Ingelheim and Lilly in the fight against kidney disease,” said LaVarne A. Burton, AKF President and CEO.
  • “Boehringer Ingelheim and Lilly are proud to continue to champion the work of the AKF by joining the Corporate Membership Program for the second consecutive year,” said Brian DiDonato, Senior Vice President, Cardio-Renal-Metabolic Brands at Boehringer Ingelheim.

Patients Mark Anniversary of Historic Kidney Executive Order

Retrieved on: 
Monday, July 10, 2023
Kidney disease, White House, Partnership, Chicago Innovation Awards, American Kidney Fund, HHS, Office of Inspector General, U.S. Department of Health and Human Services, Tomorrow's India Global Summit, Capitol Hill, Executive order, George Washington University School of Nursing, Policy, Advancing American Kidney Health, Human, Medicine, Government, Dialysis, II, Dream, Patient, Executive Order 13997, Division, Organ transplantation, USMC, Kidney, Knowledge, Mortality, Courage, III, Disease, Hypertension, Pharmaceutical industry

WASHINGTON, July 10, 2023 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the largest independent kidney patient organization in the nation, celebrated the fourth anniversary of the historic 2019 Executive Order on Advancing American Kidney Health by recognizing The Honorable Alex M. Azar, II, the 24th Secretary of the U.S. Department of Health and Human Services (HHS), with its inaugural Global Kidney Leadership and Innovation Award. The award was presented during the fifth annual Global Summit on Kidney Disease Innovations on June 28, 2023, in Washington, D.C. The Global Summit is a partnership of AAKP and The George Washington University School of Medicine and Health Sciences (GW/SMHS). The hybrid event reaches over 100 countries and has gained an audience among tens of thousands of patients and kidney stakeholders worldwide.

Key Points: 
  • WASHINGTON, July 10, 2023 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the largest independent kidney patient organization in the nation, celebrated the fourth anniversary of the historic 2019 Executive Order on Advancing American Kidney Health by recognizing The Honorable Alex M. Azar, II, the 24th Secretary of the U.S. Department of Health and Human Services (HHS), with its inaugural Global Kidney Leadership and Innovation Award.
  • The hybrid event reaches over 100 countries and has gained an audience among tens of thousands of patients and kidney stakeholders worldwide.
  • Secretary Azar, whose father was a kidney dialysis patient and kidney transplant recipient, was the architect of the Executive Order on Advancing American Kidney Health .
  • He also credited kidney patients as experts and as the "group whose knowledge, sense of urgency, and clarity about the burdens of kidney disease rises above all others."

Outset Medical to Present Research Highlighting Home Hemodialysis Success for Underserved Populations at National Kidney Foundation Spring Clinical Meetings

Retrieved on: 
Wednesday, April 12, 2023
Health, Medical Devices, Health Technology, Other Health, Managed Care, Research, Science, Abstract, ESRD, Medicine, Medicaid, Female, Freedom, PD, HHD, Chronic kidney disease, Diabetes, Workplace, Advancing American Kidney Health, Woman, Mentorship, Kidney disease, Dialysis, Nursing care plan, Medicare, Peritoneal dialysis, MD, NKF, Patient, MA, National Kidney Foundation, Coronary artery disease, ESKD, Bias, CKD, Medical device, Health insurance, Nursing, Pharmaceutical industry, Outset Contemporary Art Fund, Nephrology

“Kidney disease is debilitating and takes away the freedom of choice for patients,” said Leslie Trigg, Chair and Chief Executive Officer of Outset.

Key Points: 
  • “Kidney disease is debilitating and takes away the freedom of choice for patients,” said Leslie Trigg, Chair and Chief Executive Officer of Outset.
  • This research solidifies that all patients deserve access to options such as home hemodialysis regardless of health disparities and environmental conditions.”
    The research will be presented at the National Kidney Foundation (NKF) Spring Clinical Meetings (SCM23) in Austin, TX, which run from April 11-15.
  • Kidney professionals from around the world will attend this event to learn about new developments in nephrology.
  • The abstracts can be read in their entirety on the Outset Medical clinical evidence page .

CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit

Retrieved on: 
Wednesday, March 1, 2023
Medical Devices, Health, Surgery, Genetics, Health Technology, Biotechnology, Congress, Transplant, Medicine, Chronic kidney disease, Volunteering, National Kidney Foundation, Patient, Capitol Hill, American Society of Transplantation, Gift, 21st Century Cures Act, Kidney, Kidney disease, Advancing American Kidney Health, NKF, Education, Caregiver, Society, Pharmaceutical industry

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.
  • This marks the eighth consecutive year that CareDx is supporting NKF’s Annual Kidney Patient Summit, which is held each year in March in recognition of National Kidney Month, a time when communities across the country raise awareness about kidney disease.
  • “CareDx is proud to join forces with NKF to ensure optimal care for patients living with kidney disease and to accelerate the early detection of chronic kidney disease to help reverse or delay the need for transplantation,” said Reg Seeto, CEO and President of CareDx.
  • “On behalf of our volunteers, patients and advocates, we are deeply grateful for CareDx’s steadfast support of our Annual Kidney Patient Summit,” said Kevin Longino, transplant recipient and Chief Executive Officer at the National Kidney Foundation.

MCI Onehealth Provides Update on Subsidiary Khure Health

Retrieved on: 
Tuesday, February 7, 2023
MCI, Disease, Diagnosis, Advancing American Kidney Health, EHR, TSX, Quality of life, Risk, Chronic kidney disease, News, Health, Physician, Conditional sentence, Patient, HIV disease progression rates, Dialysis, Algorithm, Growth, Degenerative disease, Medical device, Pharmaceutical industry

TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MCI Onehealth Technologies Inc. ("MCI") (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, is pleased to provide news of a recently demonstrated positive impact on patient care from use of the technology platform provided by Khure Health, an MCI wholly-owned subsidiary that provides AI-powered clinical intelligence technology and services to physicians to support earlier diagnosis of rare diseases and now also chronic conditions.

Key Points: 
  • Khure Health is pleased to announce its first peer-reviewed publication in The Canadian Journal of Kidney Health and Disease.
  • “Khure Health’s mission is to help physicians identify rare, complex and chronic diseases earlier in their disease progression to end suffering and save lives.
  • We’re excited to be rapidly scaling the deployment of Khure Health’s clinical intelligence platform to primary care physicians and specialists across Canada and internationally,” said Dr. Alexander Dobranowski, MCI Onehealth CEO.
  • “Khure’s success is a key factor fueling MCI’s accelerating growth in higher-margin, data-driven and clinical research initiatives that have direct benefit for patients.”

KIDNEY GROUP INVITES 2023 MEDAL OF EXCELLENCE NOMINATIONS

Retrieved on: 
Wednesday, November 9, 2022
Taiwan Excellence Awards, MSN, Criterion, Social work, White House, American Board of Internal Medicine, MS, Congress, CMS, Patient, Kidney failure, Association, End Stage Renal Disease Program, Dialysis, U.S. Department of Labor, Office of Inspector General, ESRD, FMLA, CNN, Royal Canadian Legion Cadet Medal of Excellence, USMC, Health education, American Association, Medal, Nephrology, Program, American Board of Commissioners for Foreign Missions, Immunodeficiency, FAAN, DO, Kidney transplantation, Internal medicine, COVID-19, RN, Policy, FASN, Doctor of Philosophy, Transplant surgeon, Master of Science, History, Family and Medical Leave Act of 1993, Transplant, Kidney, Advancing American Kidney Health, Social media, Research, Awareness, Risk, Office of Inspector General, U.S. Department of Health and Human Services, FACP, Pharmaceutical industry, Medicine, MD, Dietitian

WASHINGTON, Nov. 9, 2022 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., has issued its call for nominations for its 2023 Medal of Excellence Award. The deadline for submissions is November 30, 2022. The AAKP Medal of Excellence Program elevates renal healthcare professionals in seven categories: Transplant Surgeon, Transplant Professional, Physician, Nurse, Social Worker, Dietitian, and Dialysis Technician.

Key Points: 
  • WASHINGTON, Nov. 9, 2022 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., has issued its call for nominations for its 2023 Medal of Excellence Award.
  • The AAKP Medal of Excellence Program elevates renal healthcare professionals in seven categories: Transplant Surgeon, Transplant Professional, Physician, Nurse, Social Worker, Dietitian, and Dialysis Technician.
  • Paul T. Conway , Chair of AAKP's Policy and Global Affairs and a 42-year kidney patient, stated, "The Medal of Excellence program is an extension of our national strategy to redefine high-quality kidney care based on the standards and needs of kidney patient consumers.
  • About the American Association of Kidney Patients (AAKP): AAKP was founded in 1969 by six dialysis patients determined to extend life-saving kidney treatments to every American at risk of kidney failure.

HIGH POTASSIUM THREAT TARGETED BY KIDNEY PATIENTS

Retrieved on: 
Wednesday, May 11, 2022
Education, CKD, Social media, White House, Research, Advancing American Kidney Health, Patient, Policy, Vifor Pharma, Dialysis, Potassium, Muscle, Cooking, Hyperkalemia, Association, Awareness, Kidney, Kidney disease, Marketing, Kidney failure, Center, U.S. Department of Defense Strategy for Operating in Cyberspace, YouTube, Diet, U.S. Department of Labor, Office of Inspector General, Heart failure, Congress, Transplant, Heart, OnDemand, American Association, Twitter, FREE, Record, PDF, AstraZeneca, Pharmaceutical industry, Facebook, Instagram

TAMPA, Fla., May 11, 2022 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest fully independent kidney patient organization in the U.S., hosted its third annual "Are You O-K+" campaign for National High Potassium Awareness Day on May 1. The 50-state educational campaign, executed by AAKP Ambassadors at the local level and online, increased awareness of the devastating effects of high potassium (known as hyperkalemia) on individuals with advanced chronic kidney disease (CKD). Nearly three million people with CKD and/or heart failure in the U.S. are estimated to be living with high potassium levels. The campaign exceeded an AAKP public education record set in 2021, with tens of thousands of participants engaged virtually and an overall 279 percent increase over 2021 online engagement.

Key Points: 
  • In a person without kidney disease, most of the extra potassium consumed in the diet is removed by the kidneys.
  • As kidney function declines in individuals with kidney disease, the body cannot get rid of excess potassium.
  • If potassium levels become too high, an individual is diagnosed with hyperkalemia (high potassium), a serious and potentially life-threatening condition.
  • "In 2022, AAKP broke all prior records for online and community reach and engagement with kidney patients, their medical teams, and our supporters throughout the kidney community.

GuideWell and Highmark Ventures Lead $35 Million Funding Round in Kidney Health Leader Healthmap Solutions

Retrieved on: 
Monday, May 2, 2022
D, Blue Cross Blue Shield Association, Nephrology, Medicare, Acos, Highmark, Windrose, CKD, Cardiology, GLOBE, Kidney disease, DCHP, NCQA, Physician, Patient, Commercial, Partnership, 21st Century Cures Act, Renal replacement therapy, Family, Hospital, Health, Medicaid, Blue, Advancing American Kidney Health, Accountable care organization, Public health, Research, Allegheny Health Network, Triple-S Management Corporation, American Association of Clinical Endocrinologists, Health insurance, Pharmaceutical industry, Risk management, GuideWell

TAMPA, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- GuideWell and Highmark Ventures lead a $35 million funding round for kidney health leader Healthmap Solutions (Healthmap), a leading NCQA accredited kidney population health management company.

Key Points: 
  • TAMPA, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- GuideWell and Highmark Ventures lead a $35 million funding round for kidney health leader Healthmap Solutions (Healthmap), a leading NCQA accredited kidney population health management company.
  • For this reason, Healthmap has built a Kidney Health Management solution to be used with our clients to deliver clinical, financial, and operational excellence.
  • Reimer added that GuideWell and Highmark Inc., who are both customers of Healthmap, conducted a comprehensive review of the kidney management market before selecting Healthmap as a partner, and later chose to invest in Healthmap.
  • Healthmap Solutions is an NCQA accredited kidney population health management company serving health plans, health systems, accountable care organizations (ACOs), and provider groups seeking a value-based solution to improve the lives of millions of Americans living with kidney disease.

Michael Hammond Appointed to the Healthmap Solutions Board of Directors

Retrieved on: 
Wednesday, April 27, 2022
Cardiology, 21st Century Cures Act, Board, CEO, Children's Hospital Los Angeles, PWC, Advancing American Kidney Health, Texas Health Resources, Salomon Brothers, Chronic kidney disease, Kidney disease, Virginia Mason Medical Center, Nephrology, Acos, Geisinger Health System, GLOBE, Patient, ESRD, CMS, Renal replacement therapy, Brown, Accountable care organization, Company, Morgan Stanley, Solution, THR, NCQA, American Association of Clinical Endocrinologists, CKD, PricewaterhouseCoopers, Baptist Health, Industry, Kidney, University, Good Samaritan Hospital (Los Angeles), Pharmaceutical industry, Wood

TAMPA, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- Healthmap Solutions (Healthmap), a fast-growing industry leader in Kidney Population Health Management, today announced the appointment of Michael Hammond, Managing Director of H2C Securities Inc., to the companys Board of Directors.

Key Points: 
  • TAMPA, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- Healthmap Solutions (Healthmap), a fast-growing industry leader in Kidney Population Health Management, today announced the appointment of Michael Hammond, Managing Director of H2C Securities Inc., to the companys Board of Directors.
  • Prior to the formation of H2C, Mr. Hammond was a co-founder of Shattuck Hammond Partners Inc.
  • Prior to joining Salomon Brothers in 1978, Mr. Hammond practiced law at Brown and Wood (now part of Sidley).
  • I am honored to be on the Board of a company that is quickly becoming the industry leader for kidney management solutions.

CLOUDCATH RECEIVES FDA CLEARANCE FOR NOVEL PERITONEAL DIALYSIS (PD) AT-HOME PATIENT MONITORING SYSTEM

Retrieved on: 
Tuesday, February 15, 2022
Health, Algorithm, Medicare, Adoption, Patient, Peritoneal dialysis, Quality of life, Food, CEO, Kidney, CMS, National Institute of Diabetes and Digestive and Kidney Diseases, Abdomen, ESRD, Entrepreneurship, Kidney failure, Chronic kidney disease, SAN, Digestive, Infection, Dialysis, IOT, Epidemiology, Goal, Pain, MDH, Kidney disease, National, National Institutes of Health, FDA, Stanford University School of Medicine, ETC, Partnership, PD, Food and Drug Administration, Advancing American Kidney Health, Machine learning, Diagnosis, National Institute, Pharmaceutical industry, Medical imaging, Medical device, Medicine, Nephrology, MD

The company plans a limited launch of the CloudCath System in the coming months with several clinics in targeted regions of the U.S.

Key Points: 
  • The company plans a limited launch of the CloudCath System in the coming months with several clinics in targeted regions of the U.S.
  • The CloudCath System delivers continuous analytics from the comfort of a patient's home with state-of-the-art technology that integrates seamlessly into the patient's daily PD protocol.
  • The CloudCath PD monitoring platform sends real-time notifications to both clinicians and patients to facilitate the patient monitoring of dialysate fluid required for safe home use of PD.
  • The CloudCath System is designed to activate the clinician/patient partnership through remotely monitoring patients' dialysis fluid, supporting higher peritoneal dialysis utilization rates, reducing high-mortality hospitalizations, maximizing the functional and social quality of patients' lives, and keeping ESRD patients on PD therapy longer.